Our editorial policy Keep exploring Vitamin B12 monograph Uses, safety profile, and every drug interaction in one place Inclisiran injection drug information The full plain-English guide to this medication Inclisiran supplement interactions Every supplement checked against Inclisiran, ranked by severity Supplement interaction checker Check any supplement or product against your medications Browse medications AZ Every drug weve checked against herbs & supplements References The 1 citations behind this page Ask a pharmacist Free, personal answer from our licensed team Still have a question about Inclisiran and Vitamin B12
He/she will refer you to a hematologist to confirm the diagnosis
Occasionally, when skin is very dry and wrinkled, we will recommend 2 treatments
Stomach acid helps to separate B12 from the protein its attached to in food, allowing it to bind with the intrinsic factor
The complete side effect frequency breakdown from Phase 2 trials: Very Common (20%+ of patients at 12mg dose) Nausea: 28% Typically mild to moderate, peaks weeks 4-8, usually resolves by week 12 Diarrhea: 24% Usually transient (1-3 weeks), rarely severe Constipation: 21% Paradoxically coexists with diarrhea in different patients Common (10-20% of patients) Vomiting: 17% Decreased appetite: 16% (beyond therapeutic effect) Injection site reactions: 14% Fatigue: 13% Dyspepsia (indigestion): 12% Headache: 11% Uncommon (2-10% of patients) Abdominal pain: 8% Dizziness: 7% Gastroesophageal reflux: 6% Hypoglycemia in diabetics on other medications: 5% Increased heart rate (average 2-4 bpm): 4% Hair thinning/loss: 3% (typically temporary) Rare but Serious (Under 2%) Pancreatitis: 0.3% (3 cases out of 1,032 patients, all resolved with discontinuation) Gallbladder events: 1.4% (expected with rapid weight loss regardless of method) Acute kidney injury: 0.7% (all cases associated with severe dehydration) KEY TAKEAWAY: About 30% experience meaningful nausea in the first 4-8 weeks
Engineering novel ionizable lipids with tunable clearance properties for lipid nanoparticles: in their latest work, Sathyajith Kumarasinghe, Juneyoung Lee, Mohindra Seepersaud at Moderna and collaborators investigated the lipophilic properties of ester-linked squaramide ionizable lipids as predictors of in vivo lipid clearance from lipid nanoparticles
